Senior Director, US Pricing & Contracting Strategy
Apply NowCompany: Summit Therapeutics plc
Location: Princeton, NJ 08540
Description:
About Summit:
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational
bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.
Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:
Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.
Overview of Role:
As a key member of the Market Access leadership team, the Senior Director, US Pricing & Contracting Strategy will lead the development and execution of pricing and contracting strategies to ensure optimal market access and reimbursement. This role demands a strategic leader with profound expertise in the US pricing and reimbursement landscape across all US customer channels, understanding the interconnectivity among various stakeholders. The individual will be responsible for all aspects of pricing and contracting, including price reporting systems, government price reporting, and contract development.
Role and Responsibilities:
Experience, Education and Specialized Knowledge and Skills:
This role is ideal for a strategic leader who can navigate the complexities of pricing and contracting in the pharmaceutical industry, ensuring compliance and optimizing market access and profitability
The pay range for this role is $221,500-$277,500 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.
Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit's Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational
bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.
Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:
- HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).
- HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
- HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.
Overview of Role:
As a key member of the Market Access leadership team, the Senior Director, US Pricing & Contracting Strategy will lead the development and execution of pricing and contracting strategies to ensure optimal market access and reimbursement. This role demands a strategic leader with profound expertise in the US pricing and reimbursement landscape across all US customer channels, understanding the interconnectivity among various stakeholders. The individual will be responsible for all aspects of pricing and contracting, including price reporting systems, government price reporting, and contract development.
Role and Responsibilities:
- Develop and manage robust price reporting systems to ensure accurate and timely reporting of pricing data
- Oversee government price reporting processes, ensuring compliance with all regulatory requirements and guidelines
- Manage relationships with outsourced service providers to ensure high-quality and efficient delivery of pricing and contracting services
- Average Sales Price (ASP) management, ensuring accurate calculation and reporting to support reimbursement strategies
- Develop and implement contract modeling strategies to optimize pricing and contracting terms, enhancing market access and profitability
- Manage contract operations, including rebates and chargebacks, to ensure efficient and compliant processing
- Lead and facilitate the pricing committee, ensuring alignment on pricing strategies and decisions across the organization
- Ensure compliance with state pricing transparency requirements, maintaining accurate and up-to-date pricing information
- Develop and maintain a comprehensive archive of price decisions to support strategic planning and compliance
- All other duties as assigned
Experience, Education and Specialized Knowledge and Skills:
- Bachelor's degree in Business, Healthcare, or a related field; advanced degree preferred
- Minimum of 12+ years of experience in pricing and contracting strategy within the pharmaceutical industry, with a focus on oncology and HCP-administered products
- Proven track record of successful management of price reporting systems and government price reporting
- Strong understanding of contract operations, including rebates and chargebacks
- Excellent strategic thinking, negotiation, and relationship management skills
- Ability to lead cross-functional teams and drive complex projects to completion
- Exceptional communication and presentation skills
- Ability to travel to support business priorities as needed
This role is ideal for a strategic leader who can navigate the complexities of pricing and contracting in the pharmaceutical industry, ensuring compliance and optimizing market access and profitability
The pay range for this role is $221,500-$277,500 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.
Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit's Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.